The development, pitched by XS Tennis & Education Foundation founder Kamau Murray, is a two-building project proposed for the vacant lot at 5301 S. State St. Named the XS Tennis Residences + Hotel, ...

Novo Nordisk (NVO-0.32%) has enjoyed tremendous success with semaglutide, the proprietary drug in Ozempic and Wegovy. However, competition is picking up with multiple next-generation drugs working ...

That means a lot of the GLP-1 drugs that Novo sells here in the U.S. are actually produced abroad, and could be subject to the threatened 50% Trump tariff. If implementation of that tariff is ...

That means a lot of the GLP-1 drugs that Novo sells here in the U.S. are actually produced abroad, and could be subject to the threatened 50% Trump tariff. If implementation of that tariff is ...

Women employed at Novo Nordisk A/S are now paid more on average than the men working at the maker of blockbuster drugs Wegovy and Ozempic, according to Danish media Finans.

Despite Lars Fruergaard Jørgensen's resignation as Novo Nordisk's CEO, its stock price has risen 10% over the past two weeks. See why NVO stock is a Strong Buy.

As for improving access to obesity treatments, Novo has, in recent months, brought down the out-of-pocket price for Wegovy. In March, it began offering a one-month supply to self-paying customers ...

Much like the long-term users of its most popular product, Novo Nordisk's (NYSE: NVO) stock has slimmed down considerably of late. Share prices of the company, which developed and sells weight ...

Novo Nordisk (NYSE: NVO) stock, maker of the blockbuster GLP-1 agonist weight-loss drugs Ozempic and Wegovy, jumped a lucky 7% through 12:20 p.m. ET Tuesday after London's Financial Times reported ...

Wegovy and Ozempic maker Novo Nordisk (NYSE: NVO) saw its stock price tick up slightly on Monday, on a media report about the possible entry of an activist investor. Market players cautiously bid ...

JM Smucker, McDonalds, Novo Nordisk. 3:43. On this episode of Stock Movers: - JM Smucker (SJM) shares fall after the company said it expects adjusted earnings of up to $9.50 a share, reduced ...

Novo Nordisk's sharp 54% decline is driven by LLY's competition, regulatory issues, and leadership change, but its fundamentals remain robust. Despite recent setbacks, NVO continues to deliver ...